Cargando…

Single antigen flow beads for identification of human leukocyte antigen antibody specificities in hypersensitized patients with chronic renal failure

AIMS OF THIS STUDY: Aims of this study were to identify class I and class II antibodies in highly sensitized patients by flow cytometry single antigen bead (FC-SAB) assay and to evaluate according to donor HLA type in order to increase their kidney transplantation chance. MATERIAL AND METHODS: We an...

Descripción completa

Detalles Bibliográficos
Autores principales: Soyöz, Mustafa, Kılıçaslan-Ayna, Tülay, Özkızılcık-Koçyiğit, Aslı, Güleç, Derya, Pirim, İbrahim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Polish Society of Experimental and Clinical Immunology 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4829810/
https://www.ncbi.nlm.nih.gov/pubmed/27095928
http://dx.doi.org/10.5114/ceji.2015.56964
Descripción
Sumario:AIMS OF THIS STUDY: Aims of this study were to identify class I and class II antibodies in highly sensitized patients by flow cytometry single antigen bead (FC-SAB) assay and to evaluate according to donor HLA type in order to increase their kidney transplantation chance. MATERIAL AND METHODS: We analyzed 60 hypersensitive patients of 351 individuals, who applied to our laboratory for PRA test in November 2013-December 2014. Flow cytometric PRA screening and single antigen bead commercial kits were used for these analyses. RESULTS: In our study group, 19 (31.7%) of these patients were male while 41 (68.3%) patients were female. The most common acceptable antigens were A*02 (10.11%), HLA-A*23 (10.11%), HLA-B*38 (8.79%) and HLA-DRB1*03 (7.83%) in hypersensitive patients. The highest antibody reactivity on SAB was observed against HLA-A*25, HLA-B*45, HLA-DRB1*04 and HLA-DRB1*08 antigens. CONCLUSIONS: The determination of these acceptable and unacceptable antigens may increase their transplantation chance. Pre-transplant HLA antibody identifications provide prognostic information with respect to the determination of patients who are at increased risk of graft loss.